Immunovia publ AB (IMMNOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunovia publ AB (IMMNOV) has a cash flow conversion efficiency ratio of -0.449x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-20.89 Million ≈ $-2.25 Million USD) by net assets (Skr46.50 Million ≈ $5.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IMMNOV net asset quality index to measure how much of total assets are equity-financed.
Immunovia publ AB - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Immunovia publ AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Immunovia publ AB debt service capacity to assess how comfortably operating cash covers total debt obligations.
Immunovia publ AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunovia publ AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IDT Australia Ltd
AU:IDT
|
-0.047x |
|
Big Pharma Split Corp Class A
TO:PRM
|
-0.011x |
|
Sapura Resources Bhd
KLSE:4596
|
0.126x |
|
Green Packet Bhd
KLSE:0082
|
0.221x |
|
Mico BioMed Co. Ltd.
KQ:214610
|
-0.315x |
|
Volcano Bhd
KLSE:0232
|
0.027x |
|
Phapros Tbk PT
JK:PEHA
|
0.064x |
|
Akdeniz Yatirim Holding AS
IS:AKYHO
|
0.058x |
Annual Cash Flow Conversion Efficiency for Immunovia publ AB (2013–2025)
The table below shows the annual cash flow conversion efficiency of Immunovia publ AB from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see IMMNOV company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr64.73 Million ≈ $6.97 Million |
Skr-78.40 Million ≈ $-8.44 Million |
-1.211x | +85.42% |
| 2024-12-31 | Skr11.65 Million ≈ $1.25 Million |
Skr-96.75 Million ≈ $-10.41 Million |
-8.306x | -278.36% |
| 2023-12-31 | Skr66.99 Million ≈ $7.21 Million |
Skr-147.06 Million ≈ $-15.83 Million |
-2.195x | -204.81% |
| 2022-12-31 | Skr243.80 Million ≈ $26.24 Million |
Skr-175.58 Million ≈ $-18.90 Million |
-0.720x | -104.71% |
| 2021-12-31 | Skr433.90 Million ≈ $46.70 Million |
Skr-152.65 Million ≈ $-16.43 Million |
-0.352x | -74.70% |
| 2020-12-31 | Skr599.40 Million ≈ $64.51 Million |
Skr-120.70 Million ≈ $-12.99 Million |
-0.201x | +21.68% |
| 2019-12-31 | Skr357.61 Million ≈ $38.48 Million |
Skr-91.95 Million ≈ $-9.90 Million |
-0.257x | -41.22% |
| 2018-12-31 | Skr461.95 Million ≈ $49.71 Million |
Skr-84.11 Million ≈ $-9.05 Million |
-0.182x | +6.91% |
| 2017-12-31 | Skr236.80 Million ≈ $25.48 Million |
Skr-46.32 Million ≈ $-4.98 Million |
-0.196x | -355.98% |
| 2016-12-31 | Skr276.63 Million ≈ $29.77 Million |
Skr-11.87 Million ≈ $-1.28 Million |
-0.043x | -26.43% |
| 2015-12-31 | Skr83.80 Million ≈ $9.02 Million |
Skr-2.84 Million ≈ $-305.99K |
-0.034x | +85.37% |
| 2014-12-31 | Skr35.74 Million ≈ $3.85 Million |
Skr-8.29 Million ≈ $-892.20K |
-0.232x | -176.53% |
| 2013-12-31 | Skr4.94 Million ≈ $531.55K |
Skr-414.31K ≈ $-44.59K |
-0.084x | -- |
About Immunovia publ AB
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.